anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Energy status is linked to the production of reactive oxygen species (ROS) in macrophages, which is elevated in obesity. However, it is unclear how ROS production is upregulated in macrophages in response to energy overload for mediating the development of obesity. Here, we show that the Rab-GTPase activating protein (RabGAP) TBC1D1, a substrate of the energy sensor AMP-activated protein kinase (AMPK), is a critical regulator of macrophage ROS production and consequent adipose inflammation for obesity development. TBC1D1 deletion decreases, whereas an energy overload-mimetic non-phosphorylatable TBC1D1S231A mutation increases, ROS production and M1-like polarization in macrophages. Mechanistically, TBC1D1 and its downstream target Rab8a form an energy-responsive complex with NOX2 for ROS generation. Transplantation of TBC1D1S231A bone marrow aggravates diet-induced obesity whereas treatment with an ultra-stable TtSOD for removal of ROS selectively in macrophages alleviates both TBC1D1S231A mutation- and diet-induced obesity. Our findings therefore have implications for drug discovery to combat obesity.
The present invention relates to compressed tablets for peroral delivery of the cannabinoid cannabidiol (CBD). More particularly, the invention provides a compressed tablet having a tablet weight of 60-1200 mg, said tablet being composed of: •50-95 wt. % of a granulate; •5-50 wt. % of lactose; and •0-30 wt. % of other tablet excipients; wherein the granulate contains: a.2-15 wt. % of cannabidiol; b.2-30 wt. % of sucrose fatty acid mono-ester; c.30-96 wt. % of lactose; and d.0-25 wt. % of other granulate excipients. The compressed tablets according to the invention can conveniently be used in the treatment of psychosis disorders or anxiety disorders. The invention further provides a method for the manufacture of the compressed tablets.
Patients who are scheduled to undergo operative tenolysis of the flexor and/or extensor tendons of the hand will be recruited. Our target enrollment is 40 patients (20 control plus 20 experimental), based on the power analysis detailed in the next paragraph. Enrolled patients will be randomized to either standard operative tenolysis, or tenolysis with placement of AlloWrap. Randomization will be performed by computerized random number generator. All surgeries will be performed by one senior fellowship-trained hand surgeon. Baseline measurements of total active motion (TAM), passive range of motion (PROM), and survey scores of the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) and Patient Rated Wrist Evaluation (PRWE) will be recorded pre-operatively. In addition, patients' pain level will be assessed using the visual analog scale (VAS) both at rest, and during the examination. These same values will be re-evaluated at post-operative follow-up visits at 2 weeks, 1 month, 3 months and 6 months. PROM will also be evaluated intra-operatively by the surgeon, and documented.
Avian antibodies that bind to influenza virus are provided. The disclosed antibodies are inexpensive to produce and are more effective than previously used antibodies against influenza. The present disclosure provides methods of treatment, prevention and diagnosis using such avian antibodies as well as methods of producing the disclosed avian antibodies. Methods of using the disclosed avian antibodies to prevent viral adhesion of influenza to cells are also provided. A novel source of such antibodies is bird eggs from countries in which vaccination against influenza of various bird populations is legally required. The present disclosure solves the problem of the limited supply of antibodies for the diagnosis, treatment, and prevention of influenza.
Adults 

The recommended dose of paliperidone extended-release tablets for the treatment of schizophrenia in adults is 6 mg administered once daily. Initial dose titration is not required. Although it has not been systematically established that doses above 6 mg have additional benefit, there was a general trend for greater effects with higher doses. This must be weighed against the dose-related increase in adverse reactions. Thus, some patients may benefit from higher doses, up to 12 mg/day, and for some patients, a lower dose of 3 mg/day may be sufficient. Dose increases above 6 mg/day should be made only after clinical reassessment and generally should occur at intervals of more than 5 days. When dose increases are indicated, increments of 3 mg/day are recommended. The maximum recommended dose is 12 mg/day. 

In a longer-term study, paliperidone extended-release tablets have been shown to be effective in delaying time to relapse in patients with schizophrenia who were stabilized on paliperidone extended-release tablets for 6 weeks [see Clinical Studies (14)]. Paliperidone extended-release tablets should be prescribed at the lowest effective dose for maintaining clinical stability and the physician should periodically reevaluate the long-term usefulness of the drug in individual patients. 

Adolescents (12 to 17 years of age) 

The recommended starting dose of paliperidone extended-release tablets for the treatment of schizophrenia in adolescents 12 to 17 years of age is 3 mg administered once daily. Initial dose titration is not required. Dose increases, if considered necessary, should be made only after clinical reassessment and should occur at increments of 3 mg/day at intervals of more than 5 days. Prescribers should be mindful that, in the adolescent schizophrenia study, there was no clear enhancement to efficacy at the higher doses, i.e., 6 mg for subjects weighing less than 51 kg and 12 mg for subjects weighing 51 kg or greater, while adverse events were dose-related.
Preoperative education will be provided by researchers to the patients on the ward before fluid intake. Solid food will be forbidden starting at 20:00 p.m, and drinking will be forbidden after 22:00 p.m the day before surgery. Group OP will consume an equal amount of water 22:00 p.m. and two hours before the surgery.
The present invention relates to enrofloxacin suspension liquid and a preparation method thereof, which belongs to the technical field of a cattle breeding drug preparation. The enrofloxacin suspension liquid of the present invention comprises the components measured by weight ratio: 8 to 12 portions of enrofloxacin, 3 to 8 portions of n-butyl oleate, 3 to 8 portions of polysorbate and 30 to 50 portions of propanediol and is added with water to 100 portions. The enrofloxacin suspension liquid of the present invention is prepared with a D phase emulsification method, and the present invention is characterized in that the enrofloxacin suspension liquid is white and slightly viscous suspension liquid. The preparation of the present invention can slowly release effective components of a drug, the bioavailability of the drug is improved, and the therapeutic effect of the drug is enhanced. The time of maintaining effective blood drug concentration can reach 48 hours through one-time medication, and suspending emulsion is used once every 2 days. The production of the preparation does not need special menstruums, and the present invention has the advantages of low cost, simple production technique and easy realization of industrialization.
The invention belongs to the field of molecular biology, relates to scFv of swine anti-PDCoV-N protein, and particularly relates to scFv of swine anti-PDCoV-N protein, and an expression vector, a construction method and application thereof. The amino acid sequence of the scFv of the swine anti-PDCoV-N protein is shown as SEQ ID No. 2. The scFv comprises a heavy chain variable region V  H  And light chain variable region V  L  Wherein the heavy chain variable region V  H  The nucleotide sequence of (2) is shown as SEQ ID NO.3 and the light chain variable region V  L  The nucleotide sequence of (2) is shown as SEQ ID NO. 4. The specific scFv-25 screened and expressed by the invention can be used for developing PDCoV diagnostic and therapeutic reagents, and can also provide assistance for further research of N protein mechanism.
TAK-659, tablet, orally, once daily along with NKTR-214, infusion, intravenously, once on Day 1 of 21-day treatment cycle, until disease progression, unacceptable toxicities, or discontinuation by participants. TAK-659 and NKTR-214 MTD/RP2D will be determined from the dose escalation phase.
A series of 12 monthly newsletters and providing education on child safety mailed to primary caregivers. This Arm crosses over to receive the Healthy Children, Strong Families intervention in Year 2.
The method and the device are used in human and veterinary medicine in the diagnostics and therapy for the energy state restoration of living organisms, tissues, organs and systems. By the method, direct effect is made on the pathologic affected organs and systems, as well as on the reasons for the disbalance in its own information field - the organism homeostasis . Any accumulated intoxication in the cells, tissues, organs and systems of the entire organism are removed. The means smoothly controls the intensity of the light energy which is directed to the biological object during therapy. By the method, information is recorded for any deviations from the normal values of human organism, and  the effect of any external pathogenic factors is tested. The effect is made by therapeutic vibrations of medicaments, medicinal herbs, food and others. Simultaneously with the investigation, neutralization of the effect of external pathogenic factors is made, a therapeutic programme is prepared and multiple comprehensive current diagnostics of the organism is made, the data produced being displayed in graphic and tabular form. The homeostasis of the somatic tissues, the internal organs and systems of the organism is restored by means of light energy in the frequency spectrum of the invisible green light. The organism is subjected to vibrations of optically activated distilled waster which is consumed until complete balance is established between the internal organs of the organism and the achievement of normal values of the biological constants in it. 2 claims, 3 figures
Cerebral aneurysms, affecting 2-5% of the global population, are often asymptomatic and commonly located within the Circle of Willis. A recent study in Neurosurgical Review highlights a significant reduction in the annual rupture rates of unruptured cerebral aneurysms (UCAs) in Japan from 2003 to 2018. By analyzing age-adjusted mortality rates of subarachnoid hemorrhage (SAH) and the number of treated ruptured cerebral aneurysms (RCAs), researchers found a substantial decrease in rupture rates-from 1.44 to 0.87% and from 0.92 to 0.76%, respectively (p < 0.001). This 88% reduction was largely attributed to improved hypertension management. Recent advancements in artificial intelligence (AI) and machine learning (ML) further support these findings. The RAPID Aneurysm software demonstrated high accuracy in detecting cerebral aneurysms on CT Angiography (CTA), while ML algorithms showed promise in predicting aneurysm rupture risk. A meta-analysis indicated that ML models could achieve 83% sensitivity and specificity in rupture prediction. Additionally, deep learning techniques, such as the PointNet + + architecture, achieved an AUC of 0.85 in rupture risk prediction. These technological advancements in AI and ML are poised to enhance early detection and risk management, potentially contributing to the observed reduction in UCA rupture rates and improving patient outcomes.
A solid cleansing, particularly personal care, especially shampoo, bar comprises from 70% to 80% by weight of a polyethylene glycol (PEG) base system having an average molecular weight between 6,500 and 8,500. The base system may comprise a mixture of PEG 6000, PEG 8000 and PEG 400. The composition includes from 12% to 20% by weight of a detergent which is typically a combination of an anionic surfactant (e.g. a lauryl sulphate) and an amphoteric surfactant (e.g. an imidazoline). Up to 12% of coactive ingredients such as foam stabilizers, pearling agents, emollients and conditioners may also be present.
PURPOSE:To provide a perfumey composition containing a methyl anthranylate derivative as an active component, emitting soft, sweet and lasting perfume of floral, fruity or herbal note and useful in the fields of food, drink, cosmetic, medicine, etc. CONSTITUTION:The objective perfumery composition contains 0.001-30 wt% compound of formula I (R is group of formula II, etc.) as an active component. The addition of the composition to a synthetic essential oil such as bergamot oil, lemon oil, etc., is effective in imparting mild, thick and lasting improving effect to the original perfume and flavor of natural essential oil. The composition harmonizes with citrus essential oil, natural essential oil (e.g. lavender oil), etc., and gives a perfumery composition having mild, thick and natural-like lasting perfume. A composition having mild, thick and highly lasting flavor can be produced when compounded to a flavor composition of e.g. strawberry, banana, etc.
Hypothesis: Once daily ART with fixed dose combination FTC/TDF/EFV will reduce viral replication to \<200 copies RNA/ml plasma in blood and other body compartments in patients with acute HIV infection, reducing infectivity. The treatment regimen will be well tolerated during treatment follow-up. A coordinated program of counseling and support will facilitate adherence and promote successful therapy. Prevalence of transmitted drug resistant HIV-1 will be assessed.

Study Design: Dual-center, prospective, single-arm pilot study of FTC/TDF/EFV in patients with acute HIV infection. Study sites will be members of the Duke-UNC Acute HIV Infection Study Consortium. Patients will be followed intensively for 96 weeks.
The invention provides dental repair lithium disilicate glass ceramic and a preparation method thereof. It is proposed to adjust the Si-Li ratio SiO on the formulation composition  2  /L i  2  O (2.0-2.9) to increase its strength. Simultaneously doping trace Rb  2  O、Cs  2  O is substituted by K  2  O((Cs  2  O+Rb  2  O)/(K  2  O‑(Cs  2  O+Rb  2  O))=0 to 1, and the batch is pre-burned at 300 to 600 ℃ for 3 to 5 hours. And then wet ball milling is carried out, so that the particle size is reduced, the melting temperature is reduced, and the energy consumption is further saved. The continuous smelting technology of the platinum crucible is introduced in the process of smelting and preparing the matrix glass, and the processes of bubbling, clarifying, stirring and the like are added, so that the microcrystalline glass material with better uniformity and more compact structure can be prepared. Finally, after the preparation of the matrix glass is finished, a 3-section nucleation and crystallization heat treatment process system is carried out so that the matrix glass has ideal crystal phase composition and structural performance.
MYDAYIS extended-release capsules contain mixed salts of a single-entity amphetamine, a CNS stimulant. MYDAYIS contains equal amounts (by weight) of four salts: dextroamphetamine sulfate and amphetamine sulfate, dextroamphetamine saccharate and amphetamine aspartate monohydrate. This results in a 3:1 mixture of dextro- to levo- amphetamine base equivalent.

The 12.5 mg, 25 mg, 37.5 mg and 50 mg strength capsules are for oral administration. They contain three types of drug-releasing beads, an immediate release and two different types of delayed release (DR) beads. The first DR bead releases amphetamine at pH 5.5 and the other DR bead releases amphetamine at pH 7.0.

Inactive Ingredients and Colors

The inactive ingredients in MYDAYIS capsules include: hard gelatin capsules, ethylcellulose, hydroxypropyl methylcellulose, methacrylic acid copolymer, methyl acrylate, methyl methacrylate, methacrylic acid copolymer, opadry beige, sugar spheres, talc, and triethyl citrate. The gelatin capsules for all four strengths contain gelatin, titanium dioxide, yellow iron oxide, and edible inks. The 12.5 mg and 25 mg strength gelatin capsules also contain FD&C Blue #2. The 37.5 mg strength also contains red iron oxide. The 50 mg strength capsule also contains D&C Red #28, D&C Red #33, and FD&C Blue #1.
OJJAARA contains momelotinib dihydrochloride monohydrate, which is a kinase inhibitor with the chemical name N‑(Cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide dihydrochloride monohydrate. It has a molecular formula of C23H22N6O2●2HCl●H2O, molecular weight of 505.40 and the following structural formula:

Momelotinib dihydrochloride monohydrate is a light yellow to brown to reddish-brown solid and is slightly soluble in water and insoluble in aqueous buffers across a pH range of 2.1 to 9. Momelotinib free base has a molecular formula of C23H22N6O2 and a molecular weight of 414.47.

OJJAARA (momelotinib) tablets are for oral administration. Each tablet contains 100 mg, 150 mg, or 200 mg of momelotinib, which is equivalent to 121.94 mg, 182.91 mg, or 243.88 mg, respectively, of momelotinib dihydrochloride monohydrate as the active ingredient. The core of each tablet contains the following inactive ingredients: lactose monohydrate, magnesium stearate, microcrystalline cellulose, propyl gallate, silicon dioxide, and sodium starch glycolate. The film coating of each tablet contains the following inactive ingredients: polyethylene glycol, polyvinyl alcohol, red iron oxide, talc, titanium dioxide, and yellow iron oxide.
Viruses having weakened ability to establish and/or maintain latency and their use as live vaccines are described. The vaccines have one or more alterations in genes that provide continued virus replication but that inhibit latency.  The vaccine materials and methods for their construction are exemplified with the varicella zoster virus. Deletion of a significant portion from both copies of the varicella zoster gene ORF63 was shown to inhibit establishment of a latent infection from a live vaccine form of the virus. Insertion of an additional ORF62 gene which is partially truncated with the ORF63 deletion inhibited establishment of latency and allowed normal growth of the virus.  Other desirable viral antigen encoding sequence(s) and/or cytokine genes advantageously may replace deleted genetic material to enhance a desired immunological response. Aspects of the discovery pertain to live vaccines of other viruses, and can provide a variety of vaccines having greater safety.
Liquid concentrates of vitamins of the B12 group are purified in a continuous process working on the countercurrent principle, and consisting of four operating stages successively merging into one another, by extracting said vitamins in a first operating stage with a solution of a halogenated phenol immersible with water, e.g. p-chlorophenol, in a solvent, e.g. hydrocarbons, halogenated hydrocarbons, carbon disulphide or mixtures thereof, washing the resulting organic phase in a second operating stage with buffer solutions having a pH range of 2.0 to 8.5 and with distilled water, converting said vitamins in a third operating stage from the organic phase into an aqueous phase by the addition of an oxygen-containing polar substance, e.g. acetone, methyl ethyl ketone, diethyl ether, dioxane, ethyl acetate, isopropanol, butanol, amyl alcohol or benzyl alcohol, and washing the aqueous solution of the said vitamins with a suitable organic solvent immiscible with water, e.g. benzene, trichlorobenzene or carbon tetrachloride, in a fourth operating stage.  Purification may be effected in single-stage or multi-stage extraction centrifuges. Examples describe the preparation of a purified aqueous Vitamin B12 extract from digested sludge and from a Streptomyces fermentation.
OBJECTIVE: Blood cultures (BCx) are important for selecting appropriate antibiotic treatment. Ordering BCx for conditions with a low probability of bacteremia has limited utility, thus improved guidance for ordering BCx is needed. Inpatient studies have implemented BCx algorithms, but no studies examine the intervention in an Emergency Department (ED) setting.
METHODS: We performed a quasi-experimental pre and postintervention study from January 12, 2020, to October 31, 2023, at a single academic adult ED and implemented a BCx algorithm. The primary outcome was the blood culture event rates (BCE per 100 ED admissions) pre and postintervention. Secondary outcomes included adverse event rates (30-day ED and hospital readmission and antibiotic days of therapy). Seven ED physicians and APP reviewed BCx for appropriateness, with monthly feedback provided to ED leadership and physicians.
RESULTS: After the BCx algorithm implementation, the BCE rate decreased from 12.17 BCE/100 ED admissions to 10.50 BCE/100 ED admissions. Of the 3,478 reviewed BCE, we adjudicated 2,153 BCE (62%) as appropriate, 653 (19%) as inappropriate, and 672 (19%) as uncertain. Adverse safety events were not statistically different pre and postintervention.
CONCLUSIONS: Implementation of an ED BCx algorithm demonstrated a reduction in BCE, without increased adverse safety events. Future studies should compare outcomes of BCx algorithm implementation in a community hospital ED without intensive chart review.
PROBLEM TO BE SOLVED: To obtain a sleep inducing cosmetic material prompting sleep by an external use thereof by blending a specific perfumery to a cosmetic material directly applied to a person wishing to be induced to sleep. SOLUTION: This sleep inducing cosmetic material is obtained by blending various sleep inducing perfumeries capable of inducing sleep. As the sleep inducing perfumery, a orris-based, a sandalwood-based and rose-based perfumeries are suitable. In the sleep inducing cosmetic, a ratio of the orris-based : sandalwood-based : rose-based perfumeries is preferably (1-8):(10-50):(2-10). As the orris-based perfumery, e.g. a natural essential oil obtained from the dried rootstock of Iris pallida belonging to the genus Iris of the family Iridaceae is used. As the sandalwood-based perfumery, e.g. a natural essential oil obtained from the pieces of wood, root, etc., of Santalum album belonging to the genus Santalum of the family Santalaceae is used.  As the rose-based perfumery, e.g. a natural essential oil obtained from the flowers of Rosa damascena, etc., belonging to the genus Rosa of family Rosaceae is used. The blending amount of the sleep inducing perfumery is preferably 0.01-10wt.%, especially 0.3-5wt.%. The sleep inducing cosmetic material is preferably used for a massage to a chest.
Citrus grandis fruit is a famous traditional Chinese medicine with various bioactivities, including cardioprotective effects. Polysaccharides are one of the key active ingredients responsible for its cardioprotective effects. This study aimed to investigate the structure and cardioprotective effect of a homogeneous polysaccharide from C. grandis fruit (CGP80-1) and explore its mechanism against myocardial ischemia-reperfusion (MI/R) injury. Structure analysis showed that CGP80-1 (11,917 Da) is an arabinan with compact coil chain conformation, containing →5)-α-L-Araf-(1→, →3,5)-α-L-Araf-(1→, and →2,3,5)-α-L-Araf-(1→ as the backbone, as well as →5)-α-L-Araf-(1→ and t-α-L-Araf as side-chains substituted at the C2 and C3 positions. Pharmacological experiments showed that pre-treatment with CGP80-1 could effectively alleviate MI/R injury by improving endogenous antioxidant enzymes and cardiac enzymes, reducing reactive oxygen species levels, and regulating apoptosis-related proteins such as caspase-3, Bax, and Bcl-2. The protective effects were correlated with the Nrf2/Keap1 and IRE1/GRP78 signaling pathways. Further analysis of structure-activity relationships revealed that the myocardial protection effects of CGP80-1 might be attributed to its appropriate molecular weight, high arabinose content, and unique compact coil chain conformation. Overall, our results provide insight into the chemical structure of CGP80-1 and its mechanism of action, suggesting that CGP80-1 could be a candidate drug for myocardial protection.